Welcome to
Texas Biologics

Investing in disease prevention and treatment

Learn more about us

Photo credit: NEXU

gloved hand with test tubes

Programs

Through our innovative programs, Texas Biologics is investing in every phase of biologic development, from research support to clinical evaluation to commercialization.

Learn More
woman in lab coat working in lab

Current Projects

UT researchers are active in the development of new biologic therapies, including enzymes, antibodies, peptides and vaccines.

Learn More

Partner With Us

There are many ways to engage with Texas Biologics, from academic collaboration to technology licensing to philanthropic support.

Learn More

Home

2024 Pilot Grant and Science Studios Awardees Announced

Texas Biologics awarded the third round of Pilot Grants to accelerate biologic technology development. In partnership with Dell Med’s HTRI, we also awarded the second cohort of Science Studios grants.

Read more about the 2024 pilot grants
Read more about the 2024 science studio awards

100+

Patents since 2012

$750M

Raised via spinoff companies

12+

Drugs in commercial use or development

News

How AI is Accelerating Discovery

AI is transforming the way scientists design cancer drugs and vaccines, study how stars form, translate brain activity into speech and turn pollution into useful products.

AI Opens Door to Safe, Effective New Antibiotics to Combat Resistant Bacteria

Protein large language models identify ways to make antibiotics better at targeting dangerous bacteria, without being toxic to humans.

McLellan Named Recipient of the 2024 IVI-SK Bioscience Park MahnHoon Award

Jason McLellan has been named the recipient of the International Vaccine Institutes Bioscience Park MahnHoon Award for his role in the development of numerous vaccines.

Texas Biologics in the Media